Authors:
Aparicio, T
Ducreux, M
Baudin, E
Sabourin, JC
De Baere, T
Mitry, E
Schlumberger, M
Rougier, P
Citation: T. Aparicio et al., Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours, EUR J CANC, 37(8), 2001, pp. 1014-1019
Authors:
Delaunoit, T
Boige, V
Belloc, J
Elias, D
Lasser, P
Duvillard, P
Ducreux, M
Citation: T. Delaunoit et al., Gastric linitis adenocarcinoma and carcinomatous meningitis: An infrequentbut aggressive association - report of four cases, ANN ONCOL, 12(6), 2001, pp. 869-871
Authors:
Saghatchian, M
Fizazi, K
Borel, C
Ducreux, M
Ruffie, P
Le Chevalier, T
Theodore, C
Citation: M. Saghatchian et al., Carcinoma of an unknown primary site: A chemotherapy strategy based on histological differentiation - results of a prospective study, ANN ONCOL, 12(4), 2001, pp. 535-540
Authors:
Peiffert, D
Giovannini, M
Ducreux, M
Michel, P
Francois, E
Lemanski, C
Mirabel, X
Cvitkovic, F
Luporsi, E
Conroy, T
Gerard, JP
Citation: D. Peiffert et al., High-dose radiation therapy and neoadjuvant plus concomitant chemotherapy with 5-fluorouracil and cisplatin in patients with locally advanced squamous-cell anal canal cancer: Final results of a phase II study, ANN ONCOL, 12(3), 2001, pp. 397-404
Authors:
Locher, C
Auperin, A
Boige, V
Alzieu, L
Pignon, JP
Abbas, M
Ducreux, M
Citation: C. Locher et al., Assessment of the cost of first line chemotherapy in metastatic colorectalcancer. Preliminary results in the FFCD 9601 trial, GASTRO CL B, 25(8-9), 2001, pp. 749-754
Authors:
Elias, D
Naudeix, E
Ducreux, M
Lusinchi, A
Goharin, A
Ouelette, JF
Lasser, P
Citation: D. Elias et al., Results of lymphadenectomy for obvious lateroaortic lymph node metastases from colorectal primaries, HEP-GASTRO, 48(37), 2001, pp. 123-127
Citation: Jp. Pignon et M. Ducreux, Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer, N ENG J MED, 344(4), 2001, pp. 306-306
Authors:
Elias, D
Blot, F
El Otmany, A
Antoun, S
Lasser, P
Boige, V
Rougier, P
Ducreux, M
Citation: D. Elias et al., Curative treatment of peritoneal carcinomatosis arising from colorectal cancer by complete resection and intraperitoneal chemotherapy, CANCER, 92(1), 2001, pp. 71-76
Authors:
Bensmaine, MA
Marty, M
de Gramont, A
Brienza, S
Levi, F
Ducreux, M
Francois, E
Gamelin, E
Bleiberg, H
Cvitkovic, E
Citation: Ma. Bensmaine et al., Factors predicting efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU) +/- folinic acid in a compassionate-use cohort of 481 5-FU-resistant advanced colorectal cancer patients, BR J CANC, 85(4), 2001, pp. 509-517
Authors:
Rougier, P
Adenis, A
Ducreux, M
de Forni, M
Bonneterre, J
Dembak, M
Clouet, P
Lebecq, A
Baille, P
Lefresne-Soulas, F
Blanc, C
Armand, JP
Citation: P. Rougier et al., A phase II study: docetaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma, EUR J CANC, 36(8), 2000, pp. 1016-1025
Authors:
Bensmaine, MA
de Gramont, A
Brienza, S
Marty, M
Levi, F
Ducreux, M
Francois, E
Gamelin, E
Bleiberg, H
Bleuzen, P
Simon, J
Cvitkovic, E
Citation: Ma. Bensmaine et al., Factors predicting for efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU)+/- folinic acid (FA) in a compassionate-use cohort of 370 5-FU-resistant advanced colorectal cancer (CRC) patients, EUR J CANC, 36(18), 2000, pp. 2335-2343
Authors:
Delord, JP
Raymond, E
Chaouche, M
Ruffie, P
Ducreux, M
Faivre, S
Boige, V
Le Chevalier, T
Rixe, O
Baudin, E
Pautier, P
Rodier, JM
Chouaki, N
Escudier, B
Kayitalire, L
Armand, JP
Citation: Jp. Delord et al., A dose-finding study of gemcitabine and vinorelbine in advanced previouslytreated malignancies, ANN ONCOL, 11(1), 2000, pp. 73-79
Authors:
Boige, V
Raymond, E
Faivre, S
Gatineau, M
Meely, K
Mekhaldi, S
Pautier, P
Ducreux, M
Rixe, O
Armand, JP
Citation: V. Boige et al., Phase I and pharmacokinetic study of the camptothecin analog DX-8951f administered as a 30-minute infusion every 3 weeks in patients with advanced cancer, J CL ONCOL, 18(23), 2000, pp. 3986-3992
Authors:
Couteau, C
Risse, ML
Ducreux, M
Lefresne-Soulas, F
Riva, A
Lebecq, A
Ruffie, P
Rougier, P
Lokiec, F
Bruno, R
Armand, JP
Citation: C. Couteau et al., Phase I and pharmacokinetic study of docetaxel and irinotecan in patients with advanced solid tumors, J CL ONCOL, 18(20), 2000, pp. 3545-3552
Authors:
Fizazi, K
Ducreux, M
Ruffie, P
Bonnay, M
Daniel, C
Soria, JC
Hill, C
Fandi, A
Poterre, M
Smith, M
Armand, JP
Citation: K. Fizazi et al., Phase I, dose-finding, and pharmacokinetic study of raltitrexed combined with oxaliplatin in patients with advanced cancer, J CL ONCOL, 18(11), 2000, pp. 2293-2300
Authors:
Francey, AM
Ducreux, M
Fassone, F
Baudin, E
Sabourin, JC
Rougier, P
Citation: Am. Francey et al., Secondary appearance of hypoglycemia in a patient with a malignant neuroendocrine pancreatic tumor, GASTRO CL B, 24(2), 2000, pp. 234-235
Authors:
Fallik, D
Sabourin, JC
Borrini, F
Jacob, S
Boige, V
Praz, F
Ducreux, M
Citation: D. Fallik et al., Responsiveness of metastatic colorectal cancers to chemotherapy with CPT11(irinotecan): possible role of the DNA mismatch repair system, GASTRO CL B, 24(10), 2000, pp. 917-922
Authors:
de Baere, T
Elias, D
Dromain, C
El Din, MG
Kuoch, V
Ducreux, M
Boige, V
Lassau, N
Marteau, V
Lasser, P
Roche, A
Citation: T. De Baere et al., Radiofrequency ablation of 100 hepatic metastases with a mean follow-up ofmore than 1 year, AM J ROENTG, 175(6), 2000, pp. 1619-1625
Authors:
O'Toole, D
Ducreux, M
Bommelaer, G
Wemeau, JL
Bouche, O
Catus, F
Blumberg, J
Ruszniewski, P
Citation: D. O'Toole et al., Treatment of carcinoid syndrome - A prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, andtolerance, CANCER, 88(4), 2000, pp. 770-776
Authors:
Antoun, S
Meshaka, P
Soltani, D
Blot, F
Ducreux, M
Lasser, P
Nitenberg, G
Elias, D
Citation: S. Antoun et al., Complications and tolerance of heated intraperitoneal chemotherapy and cytoreductive surgery for peritoneal carcinomatosis: results of a phase I-II study of peritoneal carcinomatosis from different sources, B CANCER, 87(9), 2000, pp. 665-670